Similarly, strong synergism was observed for the MEK inhibitor pimasertib combined with the PI3K-delta inhibitor idelalisib or with the BTK inhibitor ibrutinib in DLBCL (particularly the ABC type), in MCL cell lines, and in an ABC DLBCL in vivo xenograft model [183]. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.